Home World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 240 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New Treatment Helps Survivors Regain Sensation After Breast Cancer October 21, 2020 FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable... March 15, 2024 EMA Adopts Positive Opinion for Pemetrexed Baxter November 3, 2022 K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 Load more HOT NEWS Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up How Exercise Can Help You Cope With the Mental and Emotional... EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative...
